A new drug to treat Covid-19 could be available soon, Pfizer CEO Albert Bourla said on Friday and reiterated that he is against the vaccines patents waiver. He added that a third dose of the Pfizer mRNA vaccine would be needed and the vaccination should be repeated every year.
Speaking at the Delphi Economic Forum VI in Athens, Bourla said regarding the oral drug to treat Covid-19 “we should be cautious until the end of clinical trials, but the evidence so far is encouraging.”
He added that the substance the company is working on has so far been shown to kill the virus and is very safe. Any safe conclusions about the substance will be available after the summer, he stressed.
As for the vaccine against Covid-19 developed with German drugmaker BioNTech, he said he believes a third dose will be needed within 8 to 12 months after the second dose.
The immunity offer by the Pfizer/BioNTech vaccine is at least six months, he added, noting that a repeat dose would have to be given each year.
He also said that, so far, the vaccine has been able to treat all emerging mutations.